Cart
sales@molnova.com
C3a Receptor Agonist
CAS No. 944997-60-8
C3a Receptor Agonist( —— )
Catalog No. M35025 CAS No. 944997-60-8
C3a Receptor Agonist (C3a receptor agonist 1) binds the G protein-coupled C3a receptors (C3aRs) in the immune system complement pathway.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 135 | Get Quote |
|
| 5MG | 302 | Get Quote |
|
| 10MG | 511 | Get Quote |
|
| 25MG | 799 | Get Quote |
|
| 50MG | 1076 | Get Quote |
|
| 100MG | 1422 | Get Quote |
|
| 500MG | 2853 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameC3a Receptor Agonist
-
NoteResearch use only, not for human use.
-
Brief DescriptionC3a Receptor Agonist (C3a receptor agonist 1) binds the G protein-coupled C3a receptors (C3aRs) in the immune system complement pathway.
-
DescriptionC3a receptor agonist 1 (compound benzeneacetamide) is a potent C3a receptor agonist. C3a receptor agonist 1 has the potential for the research of acute inflammation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number944997-60-8
-
Formula Weight433.59
-
Molecular FormulaC27H35N3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (576.58 mM; Ultrasonic )
-
SMILESO=C(CCc1cccnc1)N1CCC(CC1)NC(=O)C(C1CCCCC1)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Trent Martin Woodruff, et al. Prevention and treatment of acute inflammatory conditions. WO2012174591A1.
molnova catalog
related products
-
BR103
BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22?±?8 ?nM.
-
BR111
BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85?±?40 ?nM.
-
ADH-503
ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.
